Melanoma - Pipeline Review, H2 2018

Melanoma - Pipeline Review, H2 2018


  • Products Id :- GMDHC11021IDB
  • |
  • Pages: 2285
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Melanoma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma-Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 18, 126, 141, 1, 11, 223, 33 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 18, 16, 75 and 11 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 12

Melanoma-Overview 13

Melanoma-Therapeutics Development 14

Melanoma-Therapeutics Assessment 80

Melanoma-Companies Involved in Therapeutics Development 114

Melanoma-Drug Profiles 240

Melanoma-Dormant Projects 2161

Melanoma-Discontinued Products 2195

Melanoma-Product Development Milestones 2200

Appendix 2213

List of Figures

Number of Products under Development for Melanoma, H2 2018 85

Number of Products under Development by Companies, H2 2018 86

Number of Products under Development by Universities/Institutes, H2 2018 107

Number of Products by Top 10 Targets, H2 2018 151

Number of Products by Stage and Top 10 Targets, H2 2018 151

Number of Products by Top 10 Mechanism of Actions, H2 2018 166

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 166

Number of Products by Routes of Administration, H2 2018 181

Number of Products by Stage and Routes of Administration, H2 2018 181

Number of Products by Top 10 Molecule Types, H2 2018 183

Number of Products by Stage and Top 10 Molecule Types, H2 2018 183

List of Tables

Number of Products under Development for Melanoma, H2 2018 85

Number of Products under Development by Companies, H2 2018 87

Number of Products under Development by Universities/Institutes, H2 2018 108

Products under Development by Companies, H2 2018 113

Products under Development by Universities/Institutes, H2 2018 144

Number of Products by Stage and Target, H2 2018 152

Number of Products by Stage and Mechanism of Action, H2 2018 167

Number of Products by Stage and Route of Administration, H2 2018 182

Number of Products by Stage and Molecule Type, H2 2018 184

Melanoma-Pipeline by 4D Pharma PLC, H2 2018 185

Melanoma-Pipeline by 4P-Pharma SAS, H2 2018 185

Melanoma-Pipeline by 4SC AG, H2 2018 186

Melanoma-Pipeline by AB Science SA, H2 2018 186

Melanoma-Pipeline by AbbVie Inc, H2 2018 187

Melanoma-Pipeline by Abivax SA, H2 2018 187

Melanoma-Pipeline by Adaptimmune Therapeutics Plc, H2 2018 188

Melanoma-Pipeline by Aduro BioTech Inc, H2 2018 188

Melanoma-Pipeline by Advanced BioDesign, H2 2018 189

Melanoma-Pipeline by Advenchen Laboratories LLC, H2 2018 189

Melanoma-Pipeline by Aeglea BioTherapeutics Inc, H2 2018 190

Melanoma-Pipeline by Afecta Pharmaceuticals Inc, H2 2018 190

Melanoma-Pipeline by Affichem SA, H2 2018 190

Melanoma-Pipeline by Agenus Inc, H2 2018 191

Melanoma-Pipeline by AGV Discovery SAS, H2 2018 191

Melanoma-Pipeline by AIMM Therapeutics BV, H2 2018 192

Melanoma-Pipeline by AiVita Biomedical Inc, H2 2018 192

Melanoma-Pipeline by Alkermes Plc, H2 2018 193

Melanoma-Pipeline by Allergy Therapeutics Plc, H2 2018 193

Melanoma-Pipeline by Alligator Bioscience AB, H2 2018 194

Melanoma-Pipeline by Altor BioScience Corp, H2 2018 194

Melanoma-Pipeline by Amgen Inc, H2 2018 195

Melanoma-Pipeline by Angimmune LLC, H2 2018 195

Melanoma-Pipeline by Antibe Therapeutics Inc, H2 2018 196

Melanoma-Pipeline by APEIRON Biologics AG, H2 2018 196

Melanoma-Pipeline by Apexigen Inc, H2 2018 196

Melanoma-Pipeline by Aphios Corp, H2 2018 197

Melanoma-Pipeline by Aposense Ltd, H2 2018 197

Melanoma-Pipeline by Aprea AB, H2 2018 198

Melanoma-Pipeline by Aptose Biosciences Inc, H2 2018 198

Melanoma-Pipeline by Arcus Biosciences Inc, H2 2018 199

Melanoma-Pipeline by ArQule Inc, H2 2018 199

Melanoma-Pipeline by Array BioPharma Inc, H2 2018 200

Melanoma-Pipeline by Asana BioSciences LLC, H2 2018 200

Melanoma-Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018 201

Melanoma-Pipeline by Astex Pharmaceuticals Inc, H2 2018 201

Melanoma-Pipeline by Atreca Inc, H2 2018 201

Melanoma-Pipeline by aTyr Pharma Inc, H2 2018 202

Melanoma-Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202

Melanoma-Pipeline by Autolus Therapeutics Plc, H2 2018 203

Melanoma-Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203

Melanoma-Pipeline by Batu Biologics Inc, H2 2018 204

Melanoma-Pipeline by Bayer AG, H2 2018 204

Melanoma-Pipeline by BeiGene Ltd, H2 2018 205

Melanoma-Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2018 205

Melanoma-Pipeline by Bellicum Pharmaceuticals Inc, H2 2018 206

Melanoma-Pipeline by BerGenBio ASA, H2 2018 206

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

4D Pharma PLC

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

Abivax SA

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced BioDesign

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Afecta Pharmaceuticals Inc

Affichem SA

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

AiVita Biomedical Inc

Alkermes Plc

Allergy Therapeutics Plc

Alligator Bioscience AB

Altor BioScience Corp

Amgen Inc

Angimmune LLC

Antibe Therapeutics Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Aprea AB

Aptose Biosciences Inc

Arcus Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Ascentage Pharma Group Corp Ltd

Astex Pharmaceuticals Inc

Atreca Inc

aTyr Pharma Inc

Aurigene Discovery Technologies Ltd

Autolus Therapeutics Plc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

BeiGene Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Biocad

Bio-Cancer Treatment International Ltd

Biogazelle NV

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioLineRx Ltd

Bionomics Ltd

BioNTech AG

Biosion Inc

Biothera Pharmaceutical Inc

BioVaxys LLC

Biovista Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BrightPath Biotherapeutics Co Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Can-Fite BioPharma Ltd

CBT Pharmaceuticals Inc

Celdara Medical LLC

Celgene Corp

Celldex Therapeutics Inc

Cellestia Biotech AG

Celprogen Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Constellation Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cue Biopharma Inc

Curevac AG

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CytoVac AS

CyTuVax BV

CZ BioMed Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DNAtrix Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eli Lilly and Co

Elsalys Biotech SA

Emcure Pharmaceuticals Ltd

EntreChem SL

eTheRNA Immunotherapies NV

Evelo Biosciences Inc

Evotec AG

Exelixis Inc

select a license
Single User License
USD 2500 INR 172925
Site License
USD 5000 INR 345850
Corporate User License
USD 7500 INR 518775

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com